<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>METTL3 inhibitors &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/mettl3-inhibitors/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 19 Jan 2026 20:03:12 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>METTL3 inhibitors &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>N6-Methyladenosine: Key RNA Modifier in Cancer Regulation</title>
		<link>https://bioengineer.org/n6-methyladenosine-key-rna-modifier-in-cancer-regulation/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 19 Jan 2026 20:02:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[and implications of N6-methyladenosine (m6A) in cancer biology and therapy]]></category>
		<category><![CDATA[Based on the content focusing on the role]]></category>
		<category><![CDATA[Cancer epigenetics** **Explanation:** 1. **m6A in cancer:** Directly states the core subject of the article. 2. **RNA methylation regulation:** Describes the broader process central]]></category>
		<category><![CDATA[here are 5 appropriate tags: **m6A in cancer]]></category>
		<category><![CDATA[m6A writers erasers readers]]></category>
		<category><![CDATA[m6A-targeted cancer therapies]]></category>
		<category><![CDATA[mechanisms]]></category>
		<category><![CDATA[METTL3 in cancer regulation]]></category>
		<category><![CDATA[METTL3 inhibitors]]></category>
		<category><![CDATA[N6-Methyladenosine RNA modification]]></category>
		<category><![CDATA[RNA methylation and immune evasion]]></category>
		<category><![CDATA[RNA methylation regulation]]></category>
		<category><![CDATA[tumor-immune microenvironment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/n6-methyladenosine-key-rna-modifier-in-cancer-regulation/</guid>

					<description><![CDATA[In the intricate landscape of molecular oncology, the role of RNA modifications has emerged as a compelling area of investigation. Among these post-transcriptional modifications, N^6-methyladenosine (m^6A) stands out as a critical player, heavily influencing gene expression and cellular function. This modification is not merely a marker of regulatory complexity but a vital determinant in the [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">318538</post-id>	</item>
	</channel>
</rss>
